Methenamine Hippurate NDC 50742-142

NDC codes

FDA NDC Directory

Product NDC (as listed)50742-142Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50742-0142Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50742-142-01	50742014201	100 TABLET in 1 BOTTLE (50742-142-01)Marketed from Dec 18, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Methenamine Hippurate
Generic name (nonproprietary): methenamine hippurate
Active ingredients: Methenamine hippurate — 1 g/1
Dosage form: Tablet
Route: Oral
Labeler: Ingenus Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210068
Marketing start: Dec 18, 2020
Listing expires: Dec 31, 2026
Identifiers: Product ID 50742-142_7fd02d91-96c5-46b0-a6d1-ebaef663f54cSPL ID 7fd02d91-96c5-46b0-a6d1-ebaef663f54cSPL set ID 4412d667-63f6-427e-a5c6-376a0e1e172dRxCUI 992150UNII M329791L57UPC 0350742142019

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450742014201 followed by a unit qualifier and the quantity

Package 50742-0142-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 23, 2023.

Indications (excerpt from the label)

INDICATIONS Methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents. To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210068

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210068
Product	Strength	Form · route	Labeler	Product NDC
Methenamine Hippurate	Methenamine hippurate 1 g/1	TabletOral	Golden State Medical Supply, Inc.	51407-880